Kathryn J Fowler

List of Publications by Year
in descending order

193 papers	7,704 citations	57758 44 h-index	64796 79 g-index
200 all docs	200 docs citations	200 times ranked	9498 citing authors

#	Article	IF	Citations
1	Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology, 2018, 289, 816-830.	7.3	634
2	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncology, The, 2016, 17, 651-662.	10.7	557
3	Gadoliniumâ€based contrast agents: A comprehensive risk assessment. Journal of Magnetic Resonance Imaging, 2017, 46, 338-353.	3.4	278
4	cHCCâ€CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 2018, 68, 113-126.	7.3	244
5	Evidence Supporting LI-RADS Major Features for CT- and MR Imagingâ€"based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. Radiology, 2018, 286, 29-48.	7.3	230
6	Assessing Radiology Research on Artificial Intelligence: A Brief Guide for Authors, Reviewers, and Readersâ€"From the <i>Radiology</i> Editorial Board. Radiology, 2020, 294, 487-489.	7.3	229
7	Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancyâ€"A Systematic Review. Gastroenterology, 2019, 156, 976-986.	1.3	221
8	Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. Gastroenterology, 2017, 153, 753-761.	1.3	209
9	2017 Version of LI-RADS for CT and MR Imaging: An Update. Radiographics, 2017, 37, 1994-2017.	3.3	185
10	Combined Hepatocellular and Cholangiocarcinoma (Biphenotypic) Tumors: Imaging Features and Diagnostic Accuracy of Contrast-Enhanced CT and MRI. American Journal of Roentgenology, 2013, 201, 332-339.	2.2	173
11	Use of Microcalcification Descriptors in BI-RADS 4th Edition to Stratify Risk of Malignancy. Radiology, 2007, 242, 388-395.	7.3	168
12	Liver fat imagingâ€"a clinical overview of ultrasound, CT, and MR imaging. British Journal of Radiology, 2018, 91, 20170959.	2.2	164
13	Hepatobiliary agents and their role in LI-RADS. Abdominal Imaging, 2015, 40, 613-625.	2.0	105
14	In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. Gastroenterology, 2016, 151, 1141-1154.e9.	1.3	100
15	Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014. Radiology, 2018, 286, 158-172.	7.3	100
16	Imaging Features of Biphenotypic Primary Liver Carcinoma (Hepatocholangiocarcinoma) and the Potential to Mimic Hepatocellular Carcinoma: LI-RADS Analysis of CT and MRI Features in 61 Cases. American Journal of Roentgenology, 2016, 207, 25-31.	2.2	96
17	Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 2274-2283.e5.	4.4	95
18	<p>LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance</p>. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 49-69.	3.7	93

#	Article	IF	Citations
19	Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. Journal of Pediatrics, 2017, 187, 141-146.e1.	1.8	91
20	Magnetic resonance imaging of focal liver lesions: Approach to imaging diagnosis. Hepatology, 2011, 54, 2227-2237.	7.3	90
21	Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdominal Radiology, 2018, 43, 218-230.	2.1	86
22	ACR Appropriateness Criteria® Right Lower Quadrant Pain-Suspected Appendicitis. Journal of the American College of Radiology, 2018, 15, S373-S387.	1.8	85
23	Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader Study. Radiology, 2018, 286, 173-185.	7.3	84
24	LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdominal Radiology, 2018, 43, 149-157.	2.1	82
25	Imaging of the Patient with Thoracic Outlet Syndrome. Radiographics, 2016, 36, 984-1000.	3.3	81
26	Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASH. Hepatology, 2020, 72, 1219-1229.	7.3	79
27	Assessment and optimization of liver volume before major hepatic resection: Current guidelines and a narrative review. International Journal of Surgery, 2018, 52, 74-81.	2.7	75
28	Imaging of Trauma in the Pregnant Patient. Radiographics, 2014, 34, 748-763.	3.3	68
29	ACR Appropriateness Criteria ® Pretreatment Staging of Colorectal Cancer. Journal of the American College of Radiology, 2017, 14, S234-S244.	1.8	66
30	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2017, 15, 127-131.e2.	4.4	66
31	PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response. CardioVascular and Interventional Radiology, 2016, 39, 855-864.	2.0	58
32	LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdominal Radiology, 2018, 43, 56-74.	2.1	58
33	PET/MRI:. Academic Radiology, 2016, 23, 220-236.	2.5	57
34	Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdominal Imaging, 2014, 39, 310-322.	2.0	56
35	In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2018, 16, 438-446.e1.	4.4	56
36	White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI. Abdominal Radiology, 2018, 43, 2625-2642.	2.1	56

#	Article	IF	Citations
37	LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdominal Radiology, 2018, 43, 75-81.	2.1	55
38	Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. Hpb, 2017, 19, 133-139.	0.3	54
39	Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography. Journal of Magnetic Resonance Imaging, 2020, 51, 25-42.	3.4	53
40	Cervical Gross Tumor Volume Dose Predicts Local Control Using Magnetic Resonance Imaging/Diffusion-Weighted Imaging–Guided High-Dose-Rate and Positron Emission Tomography/Computed Tomography–Guided Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 794-801.	0.8	52
41	Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. Journal of the American College of Surgeons, 2017, 224, 610-621.	0.5	52
42	Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018. Abdominal Radiology, 2019, 44, 2116-2132.	2.1	52
43	Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging. Hpb, 2016, 18, 296-303.	0.3	48
44	Liver Imaging Reporting and Data System: an expert consensus statement. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 29-39.	3.7	46
45	Clinical application of PET/MRI in oncology. Journal of Magnetic Resonance Imaging, 2016, 44, 265-276.	3.4	45
46	Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. Radiographics, 2020, 40, 1916-1931.	3.3	43
47	Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology, 2020, 30, 6003-6013.	4.5	43
48	Sensitivity of Endoscopic Ultrasound, Multidetector Computed Tomography, and Magnetic Resonance Cholangiopancreatography in the Diagnosis of Pancreas Divisum. Pancreas, 2013, 42, 436-441.	1.1	42
49	ACR Appropriateness Criteria® Acute Nonlocalized Abdominal Pain. Journal of the American College of Radiology, 2018, 15, S217-S231.	1.8	42
50	Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2019, 17, 1228-1238.	4.4	41
51	Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1193-1199.	4.9	40
52	ACR Appropriateness Criteria Crohn Disease. Journal of the American College of Radiology, 2015, 12, 1048-1057.e4.	1.8	39
53	New Approaches to Molecular Imaging of Multiple Myeloma. Journal of Nuclear Medicine, 2016, 57, 1-4.	5.0	39
54	LI–RADS 2017: An update. Journal of Magnetic Resonance Imaging, 2018, 47, 1459-1474.	3.4	34

#	ARTICLE	IF	CITATIONS
55	Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. Nature Medicine, 2022, 28, 430-432.	30.7	33
56	PET/MRI Evaluation of Gynecologic Malignancies and Prostate Cancer. Seminars in Nuclear Medicine, 2015, 45, 293-303.	4.6	32
57	Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary?. Urology, 2017, 102, 190-197.	1.0	32
58	Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma. Radiographics, 2021, 41, 1611-1631.	3.3	32
59	ACR Appropriateness Criteria Colorectal Cancer Screening. Journal of the American College of Radiology, 2014, 11, 543-551.	1.8	31
60	Comparative efficacy of an optimal exam between ultrasound versus abbreviated <scp>MRI</scp> for <scp>HCC</scp> screening in <scp>NAFLD</scp> cirrhosis: A prospective study. Alimentary Pharmacology and Therapeutics, 2022, 55, 820-827.	3.7	30
61	Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy. Annals of Surgical Oncology, 2015, 22, 4130-4137.	1.5	29
62	Validation of Organ Procurement and Transplant Network (OPTN)/United Network for Organ Sharing (UNOS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma. Transplantation, 2013, 95, 1506-1511.	1.0	28
63	CT/MR LI-RADS 2018: clinical implications and management recommendations. Abdominal Radiology, 2019, 44, 1306-1322.	2.1	28
64	Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease. Journal of Magnetic Resonance Imaging, 2019, 49, 1456-1466.	3.4	28
65	Deep convolutional neural network applied to the liver imaging reporting and data system (LI-RADS) version 2014 category classification: a pilot study. Abdominal Radiology, 2020, 45, 24-35.	2.1	28
66	Recommendation for terminology: Nodules without arterial phase hyperenhancement and with hepatobiliary phase hypointensity in chronic liver disease. Journal of Magnetic Resonance Imaging, 2018, 48, 1169-1171.	3.4	27
67	Cognitive Versus Software Fusion for MRI-targeted Biopsy: Experience Before and After Implementation of Fusion. Urology, 2018, 119, 115-120.	1.0	27
68	ACR Appropriateness CriteriaÂ® Left Lower Quadrant Pain-Suspected Diverticulitis. Journal of the American College of Radiology, 2019, 16, S141-S149.	1.8	26
69	Quantitative MRI of Diffuse Liver Disease: Current Applications and Future Directions. Radiology, 2019, 290, 23-30.	7.3	26
70	Imaging of tailgut cysts. Abdominal Imaging, 2015, 40, 2783-2795.	2.0	25
71	Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation. Journal of the American College of Surgeons, 2017, 225, 28-40.	0.5	24
72	Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. Journal of Pediatrics, 2018, 198, 76-83.e2.	1.8	24

#	Article	IF	Citations
73	LI-RADS and transplantation for hepatocellular carcinoma. Abdominal Radiology, 2018, 43, 193-202.	2.1	24
74	PET/MRI for the body imager: abdominal and pelvic oncologic applications. Abdominal Imaging, 2015, 40, 1387-1404.	2.0	23
75	ACR Appropriateness Criteria Â® Colorectal CancerÂScreening. Journal of the American College of Radiology, 2018, 15, S56-S68.	1.8	23
76	Measurement Repeatability of ¹⁸F-FDG PET/CT Versus ¹⁸F-FDG PET/MRI in Solid Tumors of the Pelvis. Journal of Nuclear Medicine, 2019, 60, 1080-1086.	5.0	23
77	Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LIâ€RADS). Journal of Magnetic Resonance Imaging, 2019, 49, 1236-1252.	3.4	23
78	Accuracy and Variability of Prostate Multiparametric Magnetic Resonance Imaging Interpretation Using the Prostate Imaging Reporting and Data System: A Blinded Comparison of Radiologists. European Urology Focus, 2020, 6, 267-272.	3.1	23
79	Wholeâ€body simultaneous positron emission tomography (PET)â€MR: Optimization and adaptation of MRI sequences. Journal of Magnetic Resonance Imaging, 2014, 39, 259-268.	3.4	22
80	The Role of Preoperative Dynamic Contrast-enhanced 3.0-T MR Imaging in Predicting Early Recurrence in Patients With Early-Stage Hepatocellular Carcinomas After Curative Resection. Frontiers in Oncology, 2019, 9, 1336.	2.8	22
81	Repeatability of Quantitative Brown Adipose Tissue Imaging Metrics on Positron Emission Tomography with 18F-Fluorodeoxyglucose in Humans. Cell Metabolism, 2019, 30, 212-224.e4.	16.2	21
82	Online Liver Imaging Course; Pivoting to Transform Radiology Education During the SARS-CoV-2 Pandemic. Academic Radiology, 2021, 28, 119-127.	2.5	21
83	Liver Imaging Reporting and Data System Version 2018: Impact on Categorization and Hepatocellular Carcinoma Staging. Liver Transplantation, 2019, 25, 1488-1502.	2.4	20
84	Hepatocellular adenomas: Understanding the pathomolecular lexicon, MRI features, terminology, and pitfalls to inform a standardized approach. Journal of Magnetic Resonance Imaging, 2020, 51, 1630-1640.	3.4	20
85	Presence of Magnetic Resonance Imaging Suspicious Lesion Predicts Gleason 7 or Greater Prostate Cancer in Biopsy-Naive Patients. Urology, 2016, 88, 119-124.	1.0	19
86	Crohnâ€™s Disease Is Associated With an Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study Using Magnetic Resonance Proton Density Fat Fraction Mapping. Clinical Gastroenterology and Hepatology, 2019, 17, 2816-2818.	4.4	19
87	An update for LIâ€RADS: Version 2018. Why so soon after version 2017?. Journal of Magnetic Resonance Imaging, 2019, 50, 1990-1991.	3.4	19
88	Current surgical treatment strategies for hepatocellular carcinoma in North America. World Journal of Gastroenterology, 2014, 20, 15007.	3.3	19
89	Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. European Radiology, 2022, 32, 2457-2469.	4.5	19
90	Hot spleen: hypervascular lesions of the spleen. Abdominal Imaging, 2015, 40, 2796-2813.	2.0	18

#	Article	IF	Citations
91	The Emerging Role of PET/MR Imaging in Gynecologic Cancers. PET Clinics, 2016, 11, 425-440.	3.0	18
92	User and system pitfalls in liver imaging with LI–RADS. Journal of Magnetic Resonance Imaging, 2019, 50, 1673-1686.	3.4	18
93	Considerations in Imaging Among Emergency Department Patients With Inflammatory Bowel Disease. Annals of Emergency Medicine, 2017, 69, 587-599.	0.6	17
94	Prostate MRI: a national survey of Urologist's attitudes and perceptions. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 464-471.	1.5	16
95	MRI of suspected appendicitis during pregnancy: interradiologist agreement, indeterminate interpretation and the meaning of non-visualization of the appendix. British Journal of Radiology, 2017, 90, 20170383.	2.2	16
96	Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria. Hpb, 2019, 21, 1697-1706.	0.3	16
97	Pilot study on longitudinal change in pancreatic proton density fat fraction during a weight–loss surgery program in adults with obesity. Journal of Magnetic Resonance Imaging, 2019, 50, 1092-1102.	3.4	16
98	Imaging diagnosis of hepatocellular carcinoma: LI-RADS. Chinese Clinical Oncology, 2021, 10, 3-3.	1.2	16
99	Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 513-527.	3.7	16
100	Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection. Surgery, 2018, 163, 1002-1007.	1.9	14
101	JOURNAL CLUB: Hepatopancreaticobiliary Imaging Second-Opinion Consultations: Is There Value in the Second Reading?. American Journal of Roentgenology, 2018, 211, 1264-1272.	2.2	14
102	Is It Time to Expand the Definition of Washout Appearance in LI-RADS?. Radiology, 2019, 291, 658-659.	7.3	14
103	Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors. European Radiology, 2020, 30, 996-1007.	4.5	14
104	Multimodality Imaging Approach towards Primary Aortic Sarcomas Arising after Endovascular Abdominal Aortic Aneurysm Repair: Case Series Report. CardioVascular and Interventional Radiology, 2016, 39, 940-947.	2.0	13
105	Novel Imaging Approaches in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2019, 25, 248-260.	1.9	13
106	Diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) v2017 in predicting malignant liver lesions in pediatric patients: a preliminary study. Pediatric Radiology, 2019, 49, 746-758.	2.0	13
107	Pitfalls in liver MRI: Technical approach to avoiding misdiagnosis and improving image quality. Journal of Magnetic Resonance Imaging, 2019, 49, 41-58.	3.4	13
108	How to Use LI-RADS to Report Liver CT and MRI Observations. Radiographics, 2021, 41, 1352-1367.	3.3	13

#	Article	IF	Citations
109	Liver imaging: it is time to adopt standardized terminology. European Radiology, 2022, 32, 6291-6301.	4.5	13
110	CAPTURE: Consistently Acquired Projections for Tuned and Robust Estimation. Investigative Radiology, 2018, 53, 293-305.	6.2	12
111	Cirrhosis and LI-RADS. Abdominal Radiology, 2018, 43, 26-40.	2.1	12
112	The Feasibility of Using Volumetric Phase-Contrast MR Imaging (4D Flow) to Assess for Transjugular Intrahepatic Portosystemic Shunt Dysfunction. Journal of Vascular and Interventional Radiology, 2018, 29, 1717-1724.	0.5	12
113	Living Donor Liver Transplantation: Preoperative Planning and Postoperative Complications. American Journal of Roentgenology, 2019, 213, 65-76.	2.2	12
114	Quantitative magnetic resonance imaging for chronic liver disease. British Journal of Radiology, 2021, 94, 20201377.	2.2	12
115	Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD. Radiology, 2022, , 211131.	7.3	12
116	Building successful coalitions for promoting advance care planning. American Journal of Hospice and Palliative Medicine, 2006, 23, 119-126.	1.4	11
117	Imaging Approach to Hepatocellular Carcinoma, Cholangiocarcinoma, and Metastatic Colorectal Cancer. Surgical Oncology Clinics of North America, 2015, 24, 19-40.	1.5	11
118	Liver transplantation for hepatocellular carcinoma. Current Opinion in Organ Transplantation, 2017, 22, 128-134.	1.6	11
119	Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer. EJNMMI Research, 2018, 8, 52.	2.5	11
120	Hepatic steatosis and reduction in steatosis following bariatric weight loss surgery differs between segments and lobes. European Radiology, 2019, 29, 2474-2480.	4.5	11
121	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, 1917-1925.	1.9	11
122	Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10–19 mm) HCC on extracellular contrast-enhanced MRI. Abdominal Radiology, 2021, 46, 1530-1542.	2.1	11
123	Magnetic resonance imaging–targeted vs. conventional transrectal ultrasound–guided prostate biopsy: Single-institution, matched cohort comparison. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 109.e1-109.e6.	1.6	10
124	Quantitative multiparametric MR analysis of small renal lesions: correlation with surgical pathology. Abdominal Radiology, 2018, 43, 3390-3399.	2.1	10
125	Common pitfalls when using the Liver Imaging Reporting and Data System (LI-RADS): lessons learned from a multi-year experience. Abdominal Radiology, 2019, 44, 43-53.	2.1	10
126	Magnetic resonance enterography features of small bowel Crohn's disease activity: an inter-rater reliability study of small bowel active inflammation in clinical practice setting. British Journal of Radiology, 2019, 92, 20180930.	2.2	10

#	Article	IF	Citations
127	Living Donor Liver Transplantation: Overview, Imaging Technique, and Diagnostic Considerations. American Journal of Roentgenology, 2019, 213, 54-64.	2.2	10
128	Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection. Bosnian Journal of Basic Medical Sciences, 2020, 20, 401-410.	1.0	10
129	Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. Hepatoma Research, 2020, 2020, .	1.5	10
130	Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1468-1473.	4.9	9
131	Indeterminate Findings on Oncologic PET/CT: What Difference Does PET/MRI Make?. Nuclear Medicine and Molecular Imaging, 2016, 50, 292-299.	1.0	9
132	Epidemiology of Hepatic Steatosis at a Tertiary Care Center. Academic Radiology, 2018, 25, 317-327.	2.5	9
133	The relationship between liver triglyceride composition and proton density fat fraction as assessed by 1 H MRS. NMR in Biomedicine, 2020, 33, e4286.	2.8	9
134	Hepatocellular Carcinoma Staging: Differences Between Radiologic and Pathologic Systems and Relevance to Patient Selection and Outcomes in Liver Transplantation. American Journal of Roentgenology, 2022, 218, 77-86.	2.2	9
135	Targetoid appearance on T2-weighted imaging and signs of tumor vascular involvement: diagnostic value for differentiating HCC from other primary liver carcinomas. European Radiology, 2021, 31, 6868-6878.	4.5	9
136	Practical Considerations for Clinical PET/MR Imaging. PET Clinics, 2018, 13, 97-112.	3.0	8
137	Spectrum of Pitfalls, Pseudolesions, and Misdiagnoses in Noncirrhotic Liver. American Journal of Roentgenology, 2018, 211, 97-108.	2.2	8
138	ACR Appropriateness CriteriaÂ® Palpable Abdominal Mass-Suspected Neoplasm. Journal of the American College of Radiology, 2019, 16, S384-S391.	1.8	8
139	Magnetic resonance imaging of the placenta and gravid uterus: a pictorial essay. Abdominal Radiology, 2019, 44, 669-684.	2.1	8
140	LI-RADS and transplantation: challenges and controversies. Abdominal Radiology, 2021, 46, 29-42.	2.1	8
141	Building successful coalitions to promote advance care planning. American Journal of Hospice and Palliative Medicine, 2005, 22, 437-441.	1.4	7
142	Beyond Whole-Body Imaging. Clinical Nuclear Medicine, 2015, 40, e88-e95.	1.3	7
143	Prostate Magnetic Resonance Imaging: Challenges of Implementation. Current Problems in Diagnostic Radiology, 2015, 44, 26-37.	1.4	7
144	Imaging Diagnosis of Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 623-636.	2.1	7

#	Article	IF	Citations
145	Imaging Features at the Periphery: Hemodynamics, Pathophysiology, and Effect on LI-RADS Categorization. Radiographics, 2021, 41, 1657-1675.	3.3	7
146	Magnetic resonance imaging of iatrogeny: understanding imaging artifacts related to medical devices. Abdominal Imaging, 2014, 39, 411-423.	2.0	6
147	Endovascular intervention for deep venous thrombosis in patients with inferior vena cava filters. Vascular Medicine, 2016, 21, 459-466.	1.5	6
148	A diagnosis reconsidered: the symptomatic gallbladder remnant. Journal of Hepato-Biliary-Pancreatic Sciences, 2019, 26, 137-143.	2.6	6
149	Improved survival following transarterial radioembolization of infiltrative-appearance hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 1958-1966.	2.1	6
150	Abbreviated Magnetic Resonance Imaging for HCC Surveillance. Clinical Liver Disease, 2021, 17, 133-138.	2.1	6
151	Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosis. European Radiology, 2021, 31, 8408-8419.	4.5	6
152	PET/MR imaging in gynecologic cancer: tips for differentiating normal gynecologic anatomy and benign pathology versus cancer. Abdominal Radiology, 2022, 47, 3189-3204.	2.1	6
153	Automated CNN–Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative Performance. American Journal of Roentgenology, 2022, 219, 224-232.	2.2	6
154	ACR Appropriateness Criteria® Staging of Colorectal Cancer: 2021 Update. Journal of the American College of Radiology, 2022, 19, S208-S222.	1.8	6
155	Point–of–care magnetic resonance technology to measure liver fat: Phantom and first–in–human pilot study. Magnetic Resonance in Medicine, 2022, 88, 1794-1805.	3.0	6
156	Gender and racial diversity among plenary session speakers at the Society of Abdominal Radiology Annual Meetings: a five-year assessment. Abdominal Radiology, 2022, 47, 2545-2551.	2.1	6
157	Magnetic Resonance Enterography in the Evaluation of Crohn¼s Disease. Inflammatory Bowel Diseases, 2014, 20, 2179-2188.	1.9	5
158	MRI of the stomach: a pictorial review with a focus on oncological applications and gastric motility. Abdominal Imaging, 2015, 40, 907-930.	2.0	5
159	Beyond Histologic Staging: Emerging Imaging Strategies in Colorectal Cancer with Special Focus on Magnetic Resonance Imaging. Clinics in Colon and Rectal Surgery, 2016, 29, 205-215.	1.1	5
160	Conspicuity of FDG-Avid Osseous Lesions on PET/MRI Versus PET/CT: a Quantitative and Visual Analysis. Nuclear Medicine and Molecular Imaging, 2016, 50, 228-239.	1.0	5
161	Practical Considerations for Clinical PET/MR Imaging. Magnetic Resonance Imaging Clinics of North America, 2017, 25, 281-296.	1.1	5
162	PET/MRI for Gastrointestinal Imaging. Gastroenterology Clinics of North America, 2018, 47, 691-714.	2.2	5

#	Article	IF	Citations
163	Repeatability and accuracy of various region-of-interest sampling strategies for hepatic MRI proton density fat fraction quantification. Abdominal Radiology, 2021, 46, 3105-3116.	2.1	5
164	Improved Detection of Clinically Significant Prostate Cancer With Software-assisted Systematic Biopsy Using MR/US Fusion in Patients With Negative Prostate MRI. Urology, 2018, 120, 162-166.	1.0	4
165	Multi-arterial phase MRI depicts inconsistent arterial phase hyperenhancement (APHE) subtypes in liver observations of patients at risk for hepatocellular carcinoma. European Radiology, 2021, 31, 7594-7604.	4.5	4
166	Emergency Thoracic Vascular Magnetic Resonance Imaging: Protocols and Clinical Considerations. Seminars in Roentgenology, 2014, 49, 157-168.	0.6	3
167	Peripheral Restricted Diffusion. Journal of Computer Assisted Tomography, 2015, 39, 890-895.	0.9	3
168	Magnetic resonance imaging of first trimester pregnancy: expected intrauterine contents in relation to gestational age. Abdominal Radiology, 2017, 42, 2334-2339.	2.1	3
169	Liver Imaging for Colorectal Cancer Metastases. Current Colorectal Cancer Reports, 2017, 13, 470-480.	0.5	3
170	CT Assessment of Pancreatic Cancer: What Are the Gaps in Predicting Surgical Outcomes?. Radiology, 2018, 289, 719-720.	7.3	3
171	Liver Imaging and Data System (LI-RADS) Version 2018 and Other Imaging Features in Intrahepatic Cholangiocarcinoma in Chinese Adults with vs. without Chronic Hepatitis B Viral Infection. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-10.	1.9	3
172	Impact of Pretransplantation CT on Liver Donation in Potential Deceased Organ Donors. Journal of the American College of Surgeons, 2022, 234, 166-175.	0.5	3
173	Eliciting Patient Preferences for Hepatocellular Carcinoma Screening: A Choice-Based Conjoint Analysis. Journal of the American College of Radiology, 2022, 19, 502-512.	1.8	3
174	Technical report: gadoxetate-disodium-enhanced 2D R2* mapping: a novel approach for assessing bile ducts in living donors. Abdominal Radiology, 2018, 43, 1656-1660.	2.1	2
175	Hepatocellular carcinoma: Where are we in 2018?. Current Problems in Surgery, 2018, 55, 450-503.	1.1	2
176	Examining LI-RADS recommendations: should observation size only be measured on non-arterial phases?. Abdominal Radiology, 2020, 45, 3144-3154.	2.1	2
177	Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C). European Radiology, 2020, 30, 5120-5129.	4.5	2
178	Magnetic Resonance Imaging of Nonhepatocellular Malignancies in Chronic Liver Disease. Magnetic Resonance Imaging Clinics of North America, 2021, 29, 404-418.	1.1	2
179	Automated Liver Segmentation for Quantitative MRI Analysis. Radiology, 2022, 302, 355-356.	7.3	2
180	Editorial on â€œHeadâ€‑toâ€‑Head Comparison of PIâ€‘RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancerâ€‑. Journal of Magnetic Resonance Imaging, 2020, 52, 587-588.	3.4	1

#	Article	IF	Citations
181	Accurate Prostate Volumes from Manual Calculations—A Comparison of PI-RADS v2 and v2.1 Measurement Techniques. Academic Radiology, 2021, 28, 1557-1558.	2.5	1
182	HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy. Abdominal Radiology, 2021, 46, 3686-3697.	2.1	1
183	CNN color-coded difference maps accurately display longitudinal changes in liver MRI-PDFF. European Radiology, 2021, 31, 5041-5049.	4.5	1
184	Imaging of Plasma Cell Dyscrasias with FDG-PET/MRI: A Single-Center Experience. Blood, 2016, 128, 5611-5611.	1.4	1
185	LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR–TR Lesions. Digestive Diseases and Sciences, 2022, , 1.	2.3	1
186	Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI. Hepatic Oncology, 2014, 1, 95-105.	4.2	0
187	Clinical application of PET/MRI in oncology. Journal of Magnetic Resonance Imaging, 2016, 44, spcone-spcone.	3.4	0
188	Author Reply. Urology, 2017, 102, 196-197.	1.0	0
189	PET/MRI for Gynecological Malignancies. , 2018, , 321-339.		0
190	Letter to the editor response. Abdominal Radiology, 2018, 43, 239-239.	2.1	0
191	LI-RADS v2018: a Primer and Update for Clinicians. Current Hepatology Reports, 2018, 17, 425-433.	0.9	0
192	Reply to "Letter to the editor". Abdominal Radiology, 2019, 44, 3209-3209.	2.1	0
193	MR Imaging of Diffuse Liver Disease. Magnetic Resonance Imaging Clinics of North America, 2021, 29, 347-358.	1.1	0